Patents by Inventor Julie A. Wurster

Julie A. Wurster has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Kinase inhibitors
    Patent number: 8455529
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: June 4, 2013
    Assignee: Allergan, Inc.
    Inventors: Julie A. Wurster, Richard C. Yee
  • Kinase inhibitors
    Patent number: 8455656
    Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: June 4, 2013
    Assignee: Allergan, Inc.
    Inventors: Lon T. Spada, Jane Guo Shiah, Patrick Hughes, Thomas C. Malone, Gerald W. Devries, Jeffrey L. Edelman, Julie A. Wurster, Xialing Guo, Sougato Boral
  • Kinase inhibitors
    Patent number: 8383825
    Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: February 26, 2013
    Assignee: Allergan, Inc.
    Inventors: Lon T. Spada, Jane Guo Shiah, Patrick Hughes, Thomas C. Malone, Gerald W. Devries, Jeffrey L. Edelman, Julie A. Wurster
  • Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors
    Patent number: 8338415
    Abstract: The present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof, as disclosed herein. The present invention also relates to pharmaceutical compositions comprising said compounds and to methods of using said compounds and compositions for modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: January 23, 2007
    Date of Patent: December 25, 2012
    Assignee: Allergan, Inc.
    Inventors: Xialing Guo, Zhen Zhu, Thomas C. Malone, Julie Wurster
  • Kinase inhibitors
    Publication number: 20120238558
    Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
    Type: Application
    Filed: February 26, 2009
    Publication date: September 20, 2012
    Inventors: Lon T. Spada, Jane Guo Shiah, Patrick Hughes, Thomas C. Malone, Gerald W. DeVries, Jeffrey L. Edelman, Julie A. Wurster, Xialing Guo, Sougato Boral
  • Kinase Inhibitors
    Publication number: 20120207810
    Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
    Type: Application
    Filed: February 15, 2012
    Publication date: August 16, 2012
    Inventors: Lon T. SPADA, Jane Guo SHIAH, Patrick HUGHES, Thomas C. MALONE, Gerald W. DEVRIES, Jeffrey L. EDELMAN, Julie A. WURSTER
  • SULFOXIMINES AS KINASE INHIBITORS
    Publication number: 20120196902
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: October 20, 2011
    Publication date: August 2, 2012
    Inventors: Sougato Boral, Shimiao Wang, JULIE A. WURSTER
  • Kinase inhibitors
    Patent number: 8143410
    Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
    Type: Grant
    Filed: January 5, 2009
    Date of Patent: March 27, 2012
    Assignee: Allergan, Inc.
    Inventors: Lon T. Spada, Jane Guo Shiah, Patrick Hughes, Thomas C. Malone, Gerald W. Devries, Jeffrey L. Edelman, Julie A. Wurster
  • KINASE INHIBITORS
    Publication number: 20110319460
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: September 9, 2011
    Publication date: December 29, 2011
    Applicant: ALLERGAN, INC.
    Inventors: Julie A. Wurster, Richard C. Yee
  • Kinase Inhibitors
    Publication number: 20110263611
    Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
    Type: Application
    Filed: July 7, 2011
    Publication date: October 27, 2011
    Inventors: Lon T. Spada, Jane Guo Shiah, Patrick Hughes, Thomas C. Malone, Gerald W. Devries, Jeffrey L. Edelman, Julie A. Wurster
  • Heteroaryl Dihydroindolones as Kinase Inhibitors
    Publication number: 20110257238
    Abstract: The present invention provides a compound represented by the formula: wherein the variables R1, b, R6, Y, Z, X, R and a are defined in the specification. Said compound may be used in a method for treating diseases related to unregulated tyrosine kinase signal transduction, wherein said disease is selected from the group consisting of cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, and metabolic diseases.
    Type: Application
    Filed: June 1, 2011
    Publication date: October 20, 2011
    Applicant: ALLERGAN, INC.
    Inventors: Sougato Boral, Xialing Guo, Shimiao Wang, Julie A. Wurster, Thomas C. Malone
  • Kinase inhibitors
    Patent number: 8034957
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: October 11, 2011
    Assignee: Allergan, Inc.
    Inventors: Julie A. Wurster, Richard C. Yee
  • Heteroaryl dihydroindolones as kinase inhibitors
    Patent number: 7977351
    Abstract: The present invention provides a compound represented by the formula: wherein the variables R1, b, R6, Y, Z, X, R and a are defined in the specification. Said compound may be used in a method for treating diseases related to unregulated tyrosine kinase signal transduction, wherein said disease is selected from the group consisting of cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, and metabolic diseases.
    Type: Grant
    Filed: March 16, 2007
    Date of Patent: July 12, 2011
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Xialing Guo, Shimiao Wang, Julie A. Wurster, Thomas C. Malone
  • Sulfoximines as kinase inhibitors
    Patent number: 7915443
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: March 29, 2011
    Assignee: Allergan, Inc.
    Inventors: Julie A. Wurster, Clarence Eugene Hull, III, Richard C. Yee, Sougato Boral, Shimiao Wang, Thomas C. Malone
  • Kinase inhibitors
    Patent number: 7749530
    Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: July 6, 2010
    Assignee: Allergan, Inc.
    Inventors: Lon T. Spada, Jane Guo Shiah, Patrick Hughes, Thomas C. Malone, Gerald W. DeVries, Jeffrey L. Edelman, Julie A. Wurster, Wendy M. Blanda
  • Kinase Inhibitors
    Publication number: 20100168199
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: August 10, 2007
    Publication date: July 1, 2010
    Applicant: Allengan, Inc.
    Inventors: Julie A. Wurster, Richard C. Yee
  • Kinase inhibitors
    Patent number: 7692005
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: July 12, 2006
    Date of Patent: April 6, 2010
    Assignee: Allergan, Inc.
    Inventors: Julie A. Wurster, Edward H. Wang, Richard C. Yee
  • Kinase inhibitors
    Publication number: 20090286773
    Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
    Type: Application
    Filed: February 26, 2009
    Publication date: November 19, 2009
    Inventors: Lon T. Spada, Jane Guo Shiah, Patrick Hughes, Thomas C. Malone, Gerald W. DeVries, Jeffrey L. Edelman, Julie A. Wurster, Xialing Guo, Sougato Boral
  • Kinase inhibitors
    Publication number: 20090208557
    Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
    Type: Application
    Filed: December 23, 2008
    Publication date: August 20, 2009
    Inventors: Lon T. Spada, Jane Guo Shiah, Patrick Hughes, Thomas C. Malone, Gerald W. DeVries, Jeffrey L. Edelman, Julie A. Wurster, Wendy M. Blanda
  • Kinase inhibitors
    Publication number: 20090196906
    Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
    Type: Application
    Filed: January 5, 2009
    Publication date: August 6, 2009
    Inventors: Lon T. Spada, Jane Guo Shiah, Patrick Hughes, Thomas C. Malone, Gerald W. DeVries, Jeffrey L. Edelman, Julie A. Wurster